thesi updat emerg tool analyst alway
found challeng stock quarterli volatil
one would think high multipl sensit small chang core
growth cover mani year basic realiz
one line model matter instrument growth nail
understand movement stock today beat
line write share north coupl
beat recent downgrad healthi short interest
magnitud move explain said mind
noth realli chang possibl may see improv
new product cadenc would also highlight instabl
india uncertainti china potenti offset best guess
end typic msd growth modest oper
leverag given fx headwind noth wrong
ebitda would call share fairli valu furthermor
aggress buy-back leverag recap support
share forese futur would caution get
excit buy stock least long term
return basi thu tweak forecast pt
share current trade assum settl
next day reiter rate first
quarter tend tricki given potenti
capital-expenditure volatil would recommend book profit despit
posit expect upcom analyst day
model pt updat forecast move higher sole
due slightli lesser interest rate assumpt well
carri slight core bump well mainli due new
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
product releas particularli ms ep move slightli lower
higher share price assumpt increment interest
expens aid normal ep growth pt
move equat forward ebitda
ep line recent averag
continu strength china improv eu india us
gm fx hit new product mass spec launch
opex growth sale growth look modest oper leverag similar
interest mm declin due bs util
bn expect repurch bn author
expect cash flow growth line top line growth depreci high
end histor rang sale
moder increas expens
tax vs due time discret item
repo mm
china pharma microcosm end market across rest world w/
busi small molecul qa/qc biolog develop
china pharma overal china biz gener account low-teen
europ tale citi eu weak central eu strong
strong growth industri driven materi scienc
debat point call
bioaccord new product contribut growth
biopharma growth variou put take market india return
cadenc share repo
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk valuat includ regulatori risk overal market risk well unforeseen event relat individu cover
compani broader sector includ new competit product technolog
laboratori corp america
articl articl
time dissemin januari
analyst luke sergott ross muken primarili respons prepar research report attest follow view
opinion render research report reflect person view subject compani issuer part
research analyst compens directli relat specif recommend view research report
